Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

193
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
193
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

255
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
255
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

154
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
154

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A Clinical Decision Support System to Optimize Antimicrobial Dosing in Patients with Renal Impairment.

Applied clinical informatics·2026
Same author

Good Clinical Practice Guidance for Line Materials, Filtration, and Light Protection in Intravenous Medication Administration: Modified Delphi Consensus Study.

JMIR human factors·2026
Same author

Genetic Variants Associated with Fluoropyrimidine-Induced Toxicity in Real-World Patients After Pre-Emptive <i>DPYD</i> Pharmacogenetic Testing.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Standardizing hospital pharmacy practice in home hospitalization: results from a multidisciplinary Delphi consensus in Spain.

Frontiers in public health·2025
Same author

PharmaCenter: Impact of post-discharge pharmaceutical carea consultation on medication-related problems in the emergenc department: A comprehensive analysis.

Research in social & administrative pharmacy : RSAP·2025
Same author

Cost-effectiveness of non-statin lipid-lowering therapies as an add-on to statins for achieving low-density lipoprotein cholesterol therapeutic targets in very high-risk patients in the Spanish setting.

Journal of medical economics·2025

相关实验视频

Updated: Jan 17, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.4K

关于儿科药物遗传学的最新情况.

Irene Taladriz-Sender1, Sara Salvador-Martín1, Paula Zapata-Cobo1

  • 1Servicio de Farmacia, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM). Madrid, Spain.

Anales de pediatria
|January 14, 2026
PubMed
概括

西班牙的药物遗传学应用正在增长,但在儿童中有限. 本综述分析了现有的儿科药物遗传学数据,突出了在儿童中更安全的处方的关键药物基因对.

关键词:
药物遗传学 药物遗传学药物遗传学 药物遗传学精准医学的医学儿科 儿科 儿科儿科医院 (Pediatria) 是一个儿童医院.药物遗传学 药物遗传学药物基因组学 药物基因组学精准医学是一门精准的医学.

更多相关视频

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.3K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.6K

相关实验视频

Last Updated: Jan 17, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.4K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.3K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.6K

科学领域:

  • 药物基因组学 药物基因组学
  • 儿科药理学 儿科药理学
  • 临床遗传学 临床遗传学

背景情况:

  • 由于国家卫生系统的更新和指导方针的制定,西班牙的药物遗传学实施加速了.
  • 目前的药物遗传学指南和数据主要排除了儿科患者,限制了临床应用.
  • 这种差距需要对儿科药物遗传学考虑进行专注的审查.

研究的目的:

  • 在西班牙的共同遗传服务组合内审查药物遗传测试.
  • 从国家产品特性总结 (SmPC) 和全球/国家指南中分析药物基因信息.
  • 提取和评估专门用于儿科的现有药物遗传数据.

主要方法:

  • 对遗传服务共同投资组合的系统审查.
  • 对药物遗传学建议的产品特征摘要 (SmPC) 的分析.
  • 从与儿科有关的主要全球和国家药物遗传学指南中提取和综合信息.

主要成果:

  • 确定了具有显著儿科应用的关键药物基因对,包括PPI/CYP2C19,阿巴卡维尔/HLA,沃里科纳/CYP2C19,塔克罗利穆斯/CYP3A5,阿米诺糖化物/MT-RNR1,提奥普林/TMPT/NUDT15,和阿托莫丁/CYP2D6.6.
  • 突出了当前指南中关于特定儿科建议的限制.
  • 确认了为儿科患者群体提供有针对性的药物遗传信息的需要.

结论:

  • 尽管目前存在局限性,但药物遗传学可以在监管机构和科学协会推的儿科护理中实施.
  • 进一步的研究和指导方针的制定对于扩大对儿童的药物遗传学使用至关重要.
  • 这一审查为将药物遗传学纳入西班牙儿科实践提供了基础.